1255 related articles for article (PubMed ID: 32926603)
1. Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
Chronis-Tuscano A; French W; Strickland J; Sasser T; Gonzalez ENS; Whitlock KB; Stein MA
J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926603
[TBL] [Abstract][Full Text] [Related]
2. Piloting a Sequential, Multiple Assignment, Randomized Trial for Mothers with Attention-Deficit/Hyperactivity Disorder and Their At-Risk Young Children.
Schoenfelder EN; Chronis-Tuscano A; Strickland J; Almirall D; Stein MA
J Child Adolesc Psychopharmacol; 2019 May; 29(4):256-267. PubMed ID: 30950637
[No Abstract] [Full Text] [Related]
3. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
[No Abstract] [Full Text] [Related]
5. Treating parents with attention-deficit/hyperactivity disorder: the effects of behavioral parent training and acute stimulant medication treatment on parent-child interactions.
Babinski DE; Waxmonsky JG; Pelham WE
J Abnorm Child Psychol; 2014 Oct; 42(7):1129-40. PubMed ID: 24687848
[TBL] [Abstract][Full Text] [Related]
6. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
10. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
11. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
13. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Adeyi B; Caballero B; Hodgkins P; Civil R; Coghill DR
CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling RL; Ginsberg LD; Jain R; Gao J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
16. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
[TBL] [Abstract][Full Text] [Related]
17. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
Weisler RH; Babcock T; Adeyi B; Brams M
Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
[TBL] [Abstract][Full Text] [Related]
18. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
[TBL] [Abstract][Full Text] [Related]
19. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Jacobsen L; Gunawardhana L; Johnson SA; Findling RL
J Am Acad Child Adolesc Psychiatry; 2022 Dec; 61(12):1423-1434. PubMed ID: 35577034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]